FABP4 and cancer: As with metabolic syndrome–related disorders, numerous studies of a variety of cancers, in cultured cells as well as mouse models, have shown that pharmacologic or genetic inhibition of FABP4 diminishes cell proliferation, migration, and invasiveness (71, 127, 193).